WuXi lands a lead role in Genomics England's big project

Chinese CRO WuXi PharmaTech ($WX) is on board to help Genomics England pore over samples in its massive project to sequence the genomes of 100,000 Britons. Through its NextCODE subsidiary, WuXi will help the group interpret genetic data related to cancer. NextCODE, which WuXi acquired for $65 million earlier this year, uses a huge genomic database to help physicians and investigators identify and analyze gene mutations and provide fast diagnoses. More from FierceBiotechIT

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.